Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849

Mapping and quantifying mammalian transcriptomes by RNA-Seq

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696

Primer3—new capabilities and interfaces

Untergasser, A., Cutcutache, I., Kõressaar, T., Ye, J., Faircloth, B., Remm, M., & Rozen, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,165

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool

Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Computational Prediction and Validation of Tumor-Associated Neoantigens

Roudko, V., Greenbaum, B. D., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 123

Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity

Wang, G., Chow, R. D.-W., Bai, Z., Zhu, L., Errami, Y., Dai, X., Dong, M. B., Ye, L., Zhang, X., Renauer, P. A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0500-4 · Cited by 120

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

Lopez, J. S., Powles, T. B., Braiteh, F., Siu, L. L., LoRusso, P. M., Friedman, C. F., Balmanoukian, A. S., Gordon, M. S., Yachnin, J., Rottey, S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03334-7 · Cited by 133

Opportunities for Small Molecules in Cancer Immunotherapy

van der Zanden, S. Y., Luimstra, J. J., Neefjes, J., Borst, J., & Ovaa, H. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.04.004 · Cited by 119

Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling

Park, I. A., Hwang, S.-H., Song, I. H., Heo, S., Kim, Y., Bang, W. S., Park, H. S., Lee, M., Gong, G., & Lee, H. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182786 · Cited by 124

PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy

Ochyl, L. J., Bazzill, J. D., Park, C., Xu, Y., Kuai, R., & Moon, J. J. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.016 · Cited by 121

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Li, Z., Song, W., Rubinstein, M. P., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 124

A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy

Zhao, J., Xu, Y., Ma, S., Wang, Y., Huang, Z., Qu, H., Yao, H., Zhang, Y. X., Wu, G., Huang, L., et al. (2022) · Advanced Materials · doi:10.1002/adma.202109254 · Cited by 119

Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes

Gfeller, D., Schmidt, J., Croce, G., Guillaume, P., Bobisse, S., Genolet, R., Queiroz, L., Cesbron, J., Racle, J., & Harari, A. (2023) · Cell Systems · doi:10.1016/j.cels.2022.12.002 · Cited by 128

Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations

Lee, K.-W., Yam, J. W. P., & Mao, X. (2023) · Cells · doi:10.3390/cells12172147 · Cited by 130

Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens

Pan, R., Chung, W., Chu, M.-T., Chen, S.-J., Chen, H.-C., Zheng, L., & Chung, W. (2018) · Journal of Immunology Research · doi:10.1155/2018/4325874 · Cited by 126

Past, Current, and Future of Immunotherapies for Prostate Cancer

Boettcher, A. N., Usman, A., Morgans, A., VanderWeele, D. J., Sosman, J. A., & Wu, J. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00884 · Cited by 117

New viral vectors for infectious diseases and cancer

Sasso, E., D’Alise, A. M., Zambrano, N., Scarselli, E., Folgori, A., & Nicosia, A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101430 · Cited by 120

Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model

Gebert, J. F., Gelincik, O., Özcan, M., Marshall, J. D., Hernandez‐Sanchez, A., Urban, K., Long, M. D., Cortes, E., Tosti, E., Katzenmaier, E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.073 · Cited by 120

An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes

Bjerregaard, A.-M., Nielsen, M., Jurtz, V. I., Barra, C., Hadrup, S. R., Szállási, Z., & Eklund, A. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01566 · Cited by 120

Mutation-Derived Neoantigens for Cancer Immunotherapy

Castle, J. C., Uduman, M., Pabla, S. S., Stein, R. B., & Buell, J. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01856 · Cited by 118

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Li, Y., Cong, Y., Jia, M., He, Q., Zhong, H., Zhao, Y., Li, H., Yan, M., You, J., Liu, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21241-0 · Cited by 117

Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors

Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 123

Recent advances in the bench-to-bedside translation of cancer nanomedicines

Liu, Y., Zhang, Y., Li, H., & Hu, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.007 · Cited by 127

Current RNA-based Therapeutics in Clinical Trials

Zhou, L., Qin, Z., Zhu, Y., He, Z., & Xu, T. (2019) · Current Gene Therapy · doi:10.2174/1566523219666190719100526 · Cited by 118

Turning tumors from cold to inflamed to improve immunotherapy response

Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 118

DC-Derived Exosomes for Cancer Immunotherapy

Yao, Y., Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2021) · Cancers · doi:10.3390/cancers13153667 · Cited by 117

Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity

Liu, G., Zhu, M., Zhao, X., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113889 · Cited by 114

Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer

Merlotti, A., Sadacca, B., Arribas, Y. A., Ngoma, M., Burbage, M., Goudot, C., Houy, A., Rocañín-Arjó, A., Lalanne, A. I., Seguin‐Givelet, A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abm6359 · Cited by 118

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113

Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies

Rückert, M., Deloch, L., Fietkau, R., Frey, B., Hecht, M., & Gaipl, U. S. (2018) · Strahlentherapie und Onkologie · doi:10.1007/s00066-018-1287-1 · Cited by 116

mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response

Tse, S., McKinney, K. M., Walker, W., Nguyen, M., Iacovelli, J., Small, C. G., Hopson, K., Zaks, T. Z., & Huang, E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.002 · Cited by 114

Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy

Vincent, M. P., Navidzadeh, J. O., Bobbala, S. K. R., & Scott, E. A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.006 · Cited by 117

Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy

Mukherjee, S., Mukherjee, S., Abourehab, M. A. S., Sahebkar, A., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111471 · Cited by 113

Induction of neoantigen-reactive T cells from healthy donors

Ali, M., Földvári, Z., Giannakopoulou, E., Böschen, M.-L., Strønen, E., Yang, W., Toebes, M., Schubert, B., Kohlbacher, O., Schumacher, T. N., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0170-6 · Cited by 112

Directing Traffic: How to Effectively Drive T Cells into Tumors

Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 113

Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry

Freudenmann, L. K., Marcu, A., & Stevanović, S. (2018) · Immunology · doi:10.1111/imm.12936 · Cited by 106

Recent Advances in Immunotherapy for Hepatocellular Carcinoma

Nakano, S., Eso, Y., Okada, H., Takai, A., Takahashi, K., & Seno, H. (2020) · Cancers · doi:10.3390/cancers12040775 · Cited by 109

Nanovaccine‐Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy

Qin, L., Zhang, H., Zhou, Y., Umeshappa, C. S., & Gao, H. (2021) · Small · doi:10.1002/smll.202006000 · Cited by 110

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape

Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 114

Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers

Yin, D., Zhong, Y., Ling, S., Lu, S., Wang, X., Jiang, Z., Wang, J., Dai, Y., Tian, X., Huang, Q., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01208-4 · Cited by 117

DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts

Goyal, A., Bauer, J., Hey, J., Papageorgiou, D. N., Stepanova, E., Daskalakis, M., Scheid, J., Dubbelaar, M., Klimovich, B., Schwarz, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42417-w · Cited by 102

A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge

Duperret, E. K., Perales‐Puchalt, A., Stoltz, R., Hiranjith, G. H., Mandloi, N., Barlow, J., Chaudhuri, A., Sardesai, N. Y., & Weiner, D. B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0283 · Cited by 109

Nanoparticle cancer vaccines: Design considerations and recent advances

Liu, J., Miao, L., Sui, J., Hao, Y., & Huang, G. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.10.006 · Cited by 113

Cancer cell-intrinsic mechanisms driving acquired immune tolerance

Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 116

Current landscape of mRNA technologies and delivery systems for new modality therapeutics

Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 124

Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms

Bozkus, C. C., Roudko, V., Finnigan, J. P., Mascarenhas, J. O., Hoffman, R., Iancu‐Rubin, C., & Bhardwaj, N. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1356 · Cited by 107

Therapeutic cancer vaccines: From initial findings to prospects

Song, Q., Zhang, C.-D., & Wu, X.-H. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.01.011 · Cited by 106

Hitting the Target: How T Cells Detect and Eliminate Tumors

Zamora, A. E., Crawford, J. C., & Thomas, P. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701413 · Cited by 109

TSNAdb: A Database for Tumor-Specific Neoantigens from Immunogenomics Data Analysis

Wu, J., Zhao, W., Zhou, B., Su, Z., Gu, X., Zhou, Z. M., & Chen, S. (2018) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.06.003 · Cited by 108

Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives

Chen, X., Yang, J. D., Wang, L., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.38742 · Cited by 112

Prediction of peptide mass spectral libraries with machine learning

Cox, J. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01424-w · Cited by 109

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy

Sultan, H., Takeuchi, Y., Ward, J. P., Sharma, N., Liu, T., Sukhov, V., Firulyova, M. M., Song, Y., Ameh, S., Brioschi, S., et al. (2024) · Nature · doi:10.1038/s41586-024-07752-y · Cited by 105

The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy

Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104

Formulation, characterization and evaluation of mRNA-loaded dissolvable polymeric microneedles (RNApatch)

Koh, K. J., Liu, Y., Lim, S. H., Loh, X. J., Kang, L., Lim, C. Y., & Phua, K. K. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-30290-3 · Cited by 103

Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets

Xu, C., Hong, H., Lee, Y., Park, K. S., Sun, M., Wang, T., Aikins, M. E., Xu, Y., & Moon, J. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c05062 · Cited by 104

DLpTCR: an ensemble deep learning framework for predicting immunogenic peptide recognized by T cell receptor

Xu, Z., Luo, M., Lin, W., Xue, G., Wang, P., Jin, X., Xu, C., Zhou, W., Cai, Y., Yang, W., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab335 · Cited by 108

Targeting KRAS in pancreatic cancer: new drugs on the horizon

Bannoura, S. F., Uddin, M. H., Nagasaka, M., Fazili, F., Hallak, M. N. A., Philip, P. A., El‐Rayes, B. F., & Azmi, A. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09990-2 · Cited by 112

Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction

Müller, M., Huber, F., Arnaud, M., Kraemer, A. I., Altimiras, E. R., Michaux, J., Taillandier-Coindard, M., Chiffelle, J., Murgues, B., Gehret, T., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.002 · Cited by 114

The role of cancer stem cells in the modulation of anti-tumor immune responses

Maccalli, C., Rasul, K. I., Elawad, M., & Ferrone, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.006 · Cited by 105

Neo-Antigen mRNA Vaccines

Esprit, A., de Mey, W., Shahi, R. B., Thielemans, K., Franceschini, L., & Breckpot, K. (2020) · Vaccines · doi:10.3390/vaccines8040776 · Cited by 112

mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients

Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111

Current Developments and Challenges of mRNA Vaccines

Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111

An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors

Lu, Y., Zheng, Z., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Li, Y. F., Ray, S., Franco, Z., Bliskovsky, V. V., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.018 · Cited by 105

Glycan-directed CAR-T cells

Steentoft, C., Migliorini, D., King-Peoples, T. R., Mandel, U., June, C. H., & Posey, A. D. (2018) · Glycobiology · doi:10.1093/glycob/cwy008 · Cited by 102

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

Melssen, M. M., Petroni, G. R., Chianese‐Bullock, K. A., Wages, N. A., Grosh, W. W., Varhegyi, N., Smolkin, M. E., Smith, K. T., Galeassi, N. V., Deacon, D. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0625-x · Cited by 101

Therapy of Primary Liver Cancer

Feng, M., Pan, Y., Kong, R., & Shu, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100032 · Cited by 102

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Qiu, P., Zhou, Y., Oyang, L., Wu, N., Tang, Y., Su, M., Luo, X., Wang, Y., Sheng, X., Ma, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.010 · Cited by 109

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Kalaora, S., Wolf, Y., Feferman, T., Barnea, E., Greenstein, E., Reshef, D., Tirosh, I., Reuben, A., Patkar, S., Levy, R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1418 · Cited by 101

Recent developments of RNA-based vaccines in cancer immunotherapy

Faghfuri, E., Pourfarzi, F., Faghfouri, A. H., Shadbad, M. A., Hajiasgharzadeh, K., & Baradaran, B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1815704 · Cited by 100

CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia

Biernacki, M. A., Foster, K. A., Woodward, K. B., Coon, M. E., Cummings, C. C., Cunningham, T. M., Dossa, R. G., Brault, M., Stokke, J. L., Olsen, T. M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137723 · Cited by 104

DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine

Zhang, R., Tang, L., Tian, Y., Xiao, J., Hu, Q., Zhou, B., Ding, Z., Xu, H., & Yang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.023 · Cited by 101

Cancer vaccines: current status and future directions

Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 121

Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

Cho, J. H. (2017) · Immune Network · doi:10.4110/in.2017.17.6.378 · Cited by 102

Novel strategies for cancer immunotherapy: counter-immunoediting therapy

Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 107

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection

Leal, L., Guardo, A. C., Morón‐López, S., Salgado, M., Mothe, B., Heirman, C., Pannus, P., Vanham, G., van den Ham, H., Gruters, R. A., et al. (2018) · AIDS · doi:10.1097/qad.0000000000002026 · Cited by 102

Mutation position is an important determinant for predicting cancer neoantigens

Capietto, A.-H., Jhunjhunwala, S., Pollock, S. B., Lupardus, P. J., Wong, J., Hänsch, L., Cevallos, J., Chestnut, Y., Fernandez, A., Lounsbury, N., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190179 · Cited by 99

An Update on Immunotherapy for Solid Tumors: A Review

Pham, T. D., Roth, S., Kong, J. C. H., Guerra, G., Narasimhan, V., Pereira, L. A., Desai, J., Heriot, A. G., & Ramsay, R. G. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6658-4 · Cited by 104

Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?

Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 99

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

D’Alise, A. M., Leoni, G., Cotugno, G., Troise, F., Langone, F., Fichera, I., Lucia, M. D., Avalle, L., Vitale, R., Leuzzi, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10594-2 · Cited by 98

Sensitive identification of neoantigens and cognate TCRs in human solid tumors

Arnaud, M., Chiffelle, J., Genolet, R., Rodrigo, B. N., Perez, M. A. S., Huber, F., Magnin, M., Nguyen‐Ngoc, T., Guillaume, P., Baumgaertner, P., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01072-6 · Cited by 99

Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality

Kang, T., Huang, Y., Zhu, Q., Cheng, H., Pei, Y., Feng, J., Xu, M., Jiang, G., Song, Q., Jiang, T., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.033 · Cited by 98

Does patient age influence anti-cancer immunity?

Pawelec, G. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0697-6 · Cited by 97

The neoepitope landscape of breast cancer: implications for immunotherapy

Narang, P., Chen, M., Sharma, A. A., Anderson, K. S., & Wilson, M. A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5402-1 · Cited by 95

The T cell differentiation landscape is shaped by tumour mutations in lung cancer

Ghorani, E., Reading, J. L., Henry, J. Y., de Massy, M. R., Rosenthal, R., Turati, V. A., Joshi, K., Furness, A. J. S., Aïssa, A. B., Saini, S. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0066-y · Cited by 95

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment

Yu, S., Wang, Y., He, P., Shao, B., Liu, F., Xiang, Z., Yang, T., Zeng, Y., He, T., Ma, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809304 · Cited by 101

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials

Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 102

Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors

Zhivaki, D., Kennedy, S. N., Park, J., Borriello, F., Devant, P., Cao, A., Bahleda, K. M., Murphy, S. M., Aubin, C., Evavold, C. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.026 · Cited by 102

Immunotherapies for the Treatment of Uveal Melanoma—History and Future

Schank, T. E., & Hassel, J. C. (2019) · Cancers · doi:10.3390/cancers11081048 · Cited by 97

A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors

Fang, Y., Mo, F., Shou, J., Wang, H., Luo, K., Zhang, S., Han, N., Li, H., Ye, S., Zhou, Z. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2881 · Cited by 98

5′-Phosphorothiolate Dinucleotide Cap Analogues: Reagents for Messenger RNA Modification and Potent Small-Molecular Inhibitors of Decapping Enzymes

Wojtczak, B. A., Sikorski, P. J., Fac-Dabrowska, K., Nowicka, A. M., Warmiński, M., Kubacka, D., Nowak, E., Nowotny, M., Kowalska, J., & Jemielity, J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b02597 · Cited by 95

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy

Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 95

Structure Based Prediction of Neoantigen Immunogenicity

Riley, T. P., Keller, G. L. J., Smith, A. R., Landau, L. M., Arbuiso, A. G., Devlin, J. R., & Baker, B. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02047 · Cited by 91

Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines

Vormehr, M., Türeci, Ö., & Şahin, U. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-042617-101816 · Cited by 93

Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer

Hos, B. J., Camps, M. G. M., van den Bulk, J., Tondini, E., van den Ende, T. C., Ruano, D., Franken, K. L. M. C., Janssen, G. M. C., de Ru, A. H., Filippov, D. V., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1673125 · Cited by 95

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

Bockamp, E., Rosigkeit, S., Siegl, D., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092102 · Cited by 96

The Origin and Immune Recognition of Tumor-Specific Antigens

Apavaloaei, A., Hardy, M., Thibault, P., & Perreault, C. (2020) · Cancers · doi:10.3390/cancers12092607 · Cited by 95

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

Zuazo, M., Arasanz, H., Bocanegra, A., Fernández, G., Chocarro, L., Vera, R., Kochan, G. T., & Escors, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586907 · Cited by 97

Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 98

Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance

Yang, M., Cui, M., Sun, Y., Liu, S., & Jiang, W. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01711-w · Cited by 102

Recombinant Listeria promotes tumor rejection by CD8 + T cell-dependent remodeling of the tumor microenvironment

Deng, W., Lira, V., Hudson, T. E., Lemmens, E. E., Hanson, W. G., Flores, R., Barajas, G., Katibah, G. E., Desbien, A. L., Lauer, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801910115 · Cited by 91

Immunomodulatory Effects of Radiotherapy

Kumari, S., Mukherjee, S., Sinha, D., Abdisalaam, S., Krishnan, S., & Asaithamby, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218151 · Cited by 96

Engineering nanoparticle toolkits for mRNA delivery

Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96

Chemical Modifications of mRNA Ends for Therapeutic Applications

Warminski, M., Mamot, A., Depaix, A., Kowalska, J., & Jemielity, J. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00442 · Cited by 91

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human

Aerts, J. G. J. V., de Goeje, P. L., Cornelissen, R., Kaijen-Lambers, M. E. H., Bezemer, K., van der Leest, C. H., Mahaweni, N. M., Kunert, A., Eskens, F. A. L. M., Waasdorp, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2522 · Cited by 93

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936

Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Miller, M., Loquai, C., Kloke, B., Attig, S., Bidmon, N., Bolte, S., Bukur, V., Derhovanessian, E., Diekmann, J., Filbry, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct022

Precision T-cell therapy targets tumours

Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28

Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Fritsch, E. F., Hacohen, N., & Wu, C. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-pr02

Personalized melanoma vaccines

Kelly, P. N. (2017) · Science · doi:10.1126/science.357.6353.769-b